

REMARKS

The applicant has amended claims 1 and 4 to exclude the compound of Katsushima *et al.*, thereby obviating the 102(b) rejection. Claim 7 has not been amended in this manner because Katsushima does not disclose the claimed method.


Claims 3, 6, and 9 have been amended to remove the 6th through 8th compounds, thereby obviating the § 112 rejection based on these compounds. This canceled subject matter has been moved to new claims 12-15.

Claim 7 has been further amended to clarify that it is directed to a method of treating congestive heart failure.

In view of the foregoing amendments and remarks, the applicant submits that the claims are in condition for allowance, which is respectfully solicited. If the examiner believes a teleconference will advance prosecution, he is encouraged to contact the undersigned as indicated below.

Date: February 14, 2005

Respectfully submitted,



Michael S. Greenfield
Registration No. 37,142

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, IL 60606